PD-1 and Its Ligands in Tolerance and Immunity
PD-1 и его лиганды в толерантности и иммунитете
2008-01-03
SCID: 54.1/zpqwrd7a
Discuss with AI
PD-1PD-L1T cell activationT cell toleranceimmune checkpoint
Figures from the paper
Abstract (AI)
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance. Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage. The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival. The identification of B7-1 as an additional binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance. In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.
Key Findings
1
B7-1 is an additional binding partner for PD-L1, and their inhibitory bidirectional interaction expands understanding of B7:CD28-family regulation of T-cell activation and tolerance.
2
Microorganisms and tumors exploit the PD-1:PD-L pathway to suppress antimicrobial or antitumor immunity, supporting chronic infection and tumor survival.
3
PD-1 and its ligands PD-L1 and PD-L2 deliver inhibitory signals that balance T-cell activation, immune tolerance, and immunopathology.
4
PD-1 is required for induction and maintenance of T-cell tolerance, while PD-L1 on nonhematopoietic cells limits effector responses and protects tissues from immune-mediated damage.
5
The PD-1 pathway has therapeutic potential because manipulating its immunoregulatory functions may alter tolerance, infection control, and tumor immunity.
Research Object
Programmed death 1 (PD-1) receptor and its ligands PD-L1 and PD-L2
Research Subject
Their inhibitory immunoregulatory roles in balancing T-cell activation, tolerance, immunopathology, antimicrobial and antitumor immunity, including PD-L1:B7-1 bidirectional signaling and therapeutic potential
Publication Details
Publication Date
2008-01-03
Journal
Publisher
ISSN
Cited by
5370
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by6
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer2015
Tumor biomarkers for diagnosis, prognosis and targeted therapy2024
Hepatocellular carcinoma: signaling pathways and therapeutic advances2025
Emerging phagocytosis checkpoints in cancer immunotherapy2023
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer2021
Cancer immunotherapy: the beginning of the end of cancer?2016